Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review by Vogelbaum, Michael A et al.








Phase 0 and Window of Opportunity Clinical Trial Design in
Neuro-Oncology: A RANO Review
Vogelbaum, Michael A ; Krivosheya, Daria ; Borghei-Razavi, Hamid ; Sanai, Nader ; Weller, Michael ;
Wick, Wolfgang ; Soffietti, Riccardo ; Reardon, David A ; Aghi, Manish K ; Galanis, Evanthia ; Wen,
Patrick Y ; van den Bent, Martin ; Chang, Susan
Abstract: Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics
are currently available, and much effort has been extended to identify new drugs capable of slowing
tumor progression. The phase 0 trial design was developed to facilitate early identification of promising
agents for cancer that should undergo accelerated approval. This design features an early in-human
study that enrolls a small number of patients that receive sub-therapeutic doses of medication with the
goals of describing pharmacokinetics through drug blood level measurements, and by determining intra-
tumoral concentrations of the investigational compound as well as pharmacodynamics by studying the
biochemical and physiological effects of drugs. In neuro-oncology, however, the presence of the blood-
brain barrier and difficulty in obtaining brain tumor tissue warrant a separate set of considerations. In
this manuscript, we critically reviewed the protocols used in all brain tumor related in-human phase 0
and phase 0-like (”window of opportunity”) studies between 1993 and 2018, as well as ongoing clinical
trials, and identified major challenges in trial design as applied to central nervous system tumors that
include surgical specimen collection and storage, brain tumor drug level analysis, and confirmation of
drug action. We therefore propose that phase 0 trials in neuro-oncology should include 1) only patients
in whom a resection of the tumor is planned, 2) use of clinical doses of an investigational agent, 3) tissue
sampling from enhancing and non-enhancing portions of the tumor, and 4) assessment of drug-specific
target effects. Standardization of clinical protocols for phase 0/window of opportunity studies can help
accelerate the development of effective treatments for glioblastoma.
DOI: https://doi.org/10.1093/neuonc/noaa149





Vogelbaum, Michael A; Krivosheya, Daria; Borghei-Razavi, Hamid; Sanai, Nader; Weller, Michael; Wick,
Wolfgang; Soffietti, Riccardo; Reardon, David A; Aghi, Manish K; Galanis, Evanthia; Wen, Patrick Y;
van den Bent, Martin; Chang, Susan (2020). Phase 0 and Window of Opportunity Clinical Trial Design
in Neuro-Oncology: A RANO Review. Neuro-Oncology, 22(11):1568-1579.
DOI: https://doi.org/10.1093/neuonc/noaa149
 
Phase 0 and Window of Opportunity Clinical Trial Design  
in Neuro-Oncology:  A RANO Review 
 
Michael A. Vogelbaum MD, PhD1, Daria Krivosheya MD2, Hamid Borghei-Razavi MD2, Nader 
Sanai MD3, Michael Weller MD4, Wolfgang Wick MD5, Riccardo Soffietti MD6, David A. 
Reardon MD7, Manish K. Aghi MD8, Evanthia Galanis MD9, Patrick Y. Wen MD7, Martin van 
den Bent MD10, Susan Chang MD8 
1NeuroOncology Program, Moffitt Cancer Center, 2Department of Neurosurgery, Cleveland Clinic, 3Ivy 
Brain Tumor Center, Barrow Neurological Institute, 4Department of Neurology, University Hospital and 
University of Zurich, Zurich, Switzerland, 5Department of Neurology Heidelberg University Hospital & 
German Cancer Consortium (DKTK); German Cancer Research Center (DKFZ), INF 280, D-69120 
Heidelberg, Germany, 6Department of Neuro-Oncology, University and City of Health and Science, Turin, 
Italy, 7Center For Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center and Harvard 
Medical School, 8Department of Neurosurgery, University of California, San Francisco, 9Department of 
Oncology, Mayo Clinic, Rochester, MN 55905, 10The Brain Tumor Center at Erasmus MC Cancer Institute, 
University Medical Center Rotterdam 
 
Corresponding Author: 
Michael A. Vogelbaum M.D., Ph.D. 
Program Leader of NeuroOncology and Chief of Neurosurgery 
Professor of Oncological Sciences 
Moffitt Cancer Center 
12902 Magnolia Drive 









RUNNING TITLE: Phase 0/Window of Opportunity Trials in Neuro-Oncology 
 
DISCLOSURES: 
MAV – Indirect equity and royalty interests in Infuseon Therapeutics, Inc.  Honoraria from 
Celgene, Blue Earth Diagnostics, Tocagen 
DK – None 
HB-R- None 
NS – None 
MW –  Research grants from Abbvie, Adastra, Merck, Sharp & Dohme (MSD), Merck (EMD), 
Novocure, and Roche, and honoraria for lectures or advisory board participation or consulting 
from Abbvie, Bristol Meyers Squibb, Celgene, MSD, Merck (EMD), Orbus, Roche and Tocagen 
WW – None 
RS –  None 
DR – Research support (paid to DFCI): Acerta Phamaceuticals; Agenus; Celldex; EMD Serono; 
Incyte; Midatech; Omniox; Tragara.  Advisory/consultation (Paid to DR): Abbvie; Agenus; 
Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; 
Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc. 
MKA –  None 
EG – Research support (paid to MC): Merck KGaA, Bristol-Myers Squibb, Genentech, Tracon; 
Advisory/Consultation (paid to MC): Genentech/Roche, Abbvie; Advisory/Consultation (to EG): 
Celgene, Oncorus, Kiyatec 
PW – Advisory Board:Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic 




; Speaker: Merck, Prime Oncology; DSMB: Tocagen 
MvdB – honoraria from Abbvie, Celgene, BMS, Vaximm, Agios 
SC –  Institutional research support: Agios, Novartis 
 
AUTHORSHIP: 
Design:  MAV, DK, HB-R, PW, MvdB, SC 
Implementation:  MAV, DK, HB-R 
Analysis:  MAV, DK, HB-R 
Interpretation and manuscript writing:  All authors 







Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics are 
currently available, and much effort has been extended to identify new drugs capable of slowing 
tumor progression. The phase 0 trial design was developed to facilitate early identification of 
promising agents for cancer that should undergo accelerated approval. This design features an 
early in-human study that enrolls a small number of patients that receive sub-therapeutic doses of 
medication with the goals of describing pharmacokinetics through drug blood level measurements, 
and by determining intra-tumoral concentrations of the investigational compound as well as 
pharmacodynamics by studying the biochemical and physiological effects of drugs. In neuro-
oncology, however, the presence of the blood-brain barrier and difficulty in obtaining brain tumor 
tissue warrant a separate set of considerations.  In this manuscript, we critically reviewed the 
protocols used in all brain tumor related in-human phase 0 and phase 0-like (“window of 
opportunity”) studies between 1993 and 2018, as well as ongoing clinical trials, and identified 
major challenges in trial design as applied to central nervous system tumors that include surgical 
specimen collection and storage, brain tumor drug level analysis, and confirmation of drug action. 
We therefore propose that phase 0 trials in neuro-oncology should include 1) only patients in whom 
a resection of the tumor is planned, 2) use of clinical doses of an investigational agent, 3) tissue 
sampling from enhancing and non-enhancing portions of the tumor, and 4) assessment of drug-
specific target effects. Standardization of clinical protocols for phase 0/window of opportunity 
studies can help accelerate the development of effective treatments for glioblastoma.  
  





• Most clinical investigations of novel drugs for gliomas do not account for the ability of 
these drugs to access their targets in the CNS 
• Incorporation of elements of Phase 0/Window of Opportunity clinical trial designs into 
neuro-oncology trials will permit a greater understanding of the potential for a novel agent 
to generate meaningful clinical responses. 
 
IMPORTANCE OF THE STUDY: 
Few effective chemotherapeutics are currently available for treating glioblastoma despite 
extensive clinical investigation of a multitude of compounds. The presence of a blood-brain-barrier 
makes it challenging to rely on the pharmacokinetics and pharmacodynamics that are generated 
from investigations in systemic cancers.  Phase 0/Window of Opportunity clinical trial designs can 
be used to determine the intra-tumoral concentrations of the investigational compound as well as 
pharmacodynamics by studying the biochemical and physiological effects of drugs in tumor tissue.  
We reviewed all brain tumor related in-human phase 0/Window of Opportunity studies between 
1993 and 2018 and identified major challenges in neuro-oncology clinical trial design. We propose 
that phase 0 trials in neuro-oncology should include 1) only patients in whom a resection of the 
tumor is planned, 2) use of clinical doses of an investigational agent, 3) tissue sampling from 
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O6-BG – O6-Benzyl-Guanine 
IHC – Immunohistochemistry  







Glioblastoma is the most common malignant primary brain neoplasm.1  The median survival after 
initial diagnosis is less than one year without treatment.2 Surgical resection alone is insufficient to 
control tumor progression given that glioblastoma is an infiltrative disease. The addition of 
radiation and chemotherapy significantly improves median patient survival to 14-16 months in 
clinical trial populations,3 and this may be further extended by use of tumor-treating fields.4 
Despite intensive research and numerous clinical trials, no chemotherapeutic drug except 
temozolomide has been proven effective at unequivocally slowing the relentless growth of this 
devastating neoplasm in a randomized clinical trial. Facilitating early clinical testing of promising 
targets can have a meaningful impact on improving our ability to conduct trials on agents that hold 
real promise for survival benefit.  
 
There have been significant advances made in oncologic drug discovery in the last several decades. 
The path that a drug has to take from the laboratory through to FDA approval has remained 
unchanged, however.5 With only 5-10% of new molecules advancing past initial stages of 
development, there is a great need to develop protocols that would allow early efficient testing of 
adequate drug penetration and sufficient biological efficacy of novel targeted agents.6 An 
important goal of these studies is to obtain signals that suggest promise for further studies or that 
indicate futility for compounds that are unlikely to be effective. 
 
New scientific approaches and regulatory guidelines have been proposed to shorten the drug 
development timeline by streamlining clinical models that test drug distribution and biological 




systemic and ideally intratumoral pharmacokinetic and pharmacodynamic parameters into an 
early-phase study design.7 Phase 0 studies can take various forms, but typically refer to non-
therapeutic, first-in-human studies enrolling a small number of patients (typically 10-12), 
involving limited drug exposures (often as a microdose), and incorporating pre- and post-drug 
tissue biopsies (Table 1).8,9 A significant step in the direction of enabling phase 0 trial designs was 
the FDA’s announcement of the Exploratory Investigational New Drug (IND) mechanism in 2006.  
 
The goal of a phase 0 study is to examine the pharmacological effects of the compound on patient 
tumors at an early stage of drug development. In assessing the drug’s penetration into tumor tissue 
and modulation of its target(s) in an early stage of its development, the results can identify whether 
a candidate agent’s trajectory is suitable for acceleration or if that agent’s clinical study should be 
held pending further preclinical optimization.10  Since subtherapeutic exposure of drugs or 
therapeutic exposure for a limited number of doses are typically employed, the risk to the patient 
from the study agent is extraordinarily low,11 as is the likelihood of benefit, however (see below). 
Still, this trial design shortens the preclinical stage of drug development by providing in vivo 
information from patients and their tumors, which is critical for drug development and could not 
be obtained via any other mechanism.8  
 
Execution of a Phase 0 clinical trial requires many considerations. Target selection must be 
optimized with appropriate preclinical biochemical and animal modeling. Pharmacokinetic assays 
to determine drug concentrations must be validated to provide a consistent assessment of drug 
content in tissues. The risks to the patient are less than conventional early phase investigation, 




associated with tumor or tissue sampling and the potential delay of participation in therapeutic 
clinical trials unless patients are allowed to stay on the experimental agent in seamless phase 0 to 
1/2 transitions.  From an ethical standpoint, their enrollment in a non-therapeutic drug study is 
justified by collective benefit of early human data on a prospective agent and its utility in 
accelerating subsequent phase 1, 2, or 3 studies.11 
 
One of the major objectives of a phase 0 study is to demonstrate the biochemical effect of drug 
exposure, i.e. alteration in pathway activity as a result of drug action. This evaluation is optimally 
coupled to measurement of drug levels within the tumor to distinguish circumstances when a drug 
fails to exert its biological effect due to low tumor concentrations, versus instances when high 
tumor levels are achieved but the drug does not successfully interact with its intended target in 
vivo.  Such determination requires drug administration at a dose level that is expected to be 
effective. 
 
In neuro-oncology, there are special considerations with respect to implementation of the phase 0 
study design. The presence of the blood brain barrier creates a separate physiological compartment 
that many molecules cannot cross.12 Therefore, serum drug levels are unlikely to reflect drug 
exposure of the tumor.13 Consequently, microdosing is also not a practical approach in neuro-
oncology, as such low doses are likely to confound efforts to measure intra-tumoral concentrations. 
Furthermore, frequently only a limited number of tissue samples can be obtained safely and 
potential complications, such as hemorrhage, can have a devastating outcome, more so than in 
non-CNS tumors. Therefore, each sample that is obtained for the study needs to be strategically 





The goal of this report is to extensively review previously published phase 0 or phase 0-like 
(“window of opportunity”) clinical studies performed in the setting of glioblastoma that included 
evaluation of tumor pharmacodynamics of a therapeutic drug.  Our goals were to critically analyze 
the protocols used in each study and to derive guidelines for future phase 0 studies applicable 
specifically to the development of therapeutics for CNS disease.  
 
METHODS 
This project was developed within the scope of the Response in NeuroOncology Working Group 
(RANO) and endorsed by its steering committee (including the following authors: MAV, MvdB, 
SC, PW). 
Search methodology 
A literature search of PubMed and EMBASE was conducted to include all studies up to December, 
2019.  The specific search terms included in various combinations “phase 0”, “phase 1”, “phase 
2”, “glioblastoma”, “glioma”, “malignant brain tumors”, “human brain tumor tissue”, 
“pharmacokinetics” and “pharmacodynamics”. Studies were limited to those involving drugs, and 
not biologics (e.g. antibodies, engineered proteins, viral vectors, oncolytic viruses, etc.).  The 
search results were filtered and restricted to studies or clinical trials in humans with abstracts and 
full manuscripts, excluding reports that were limited to conference or congress abstracts. After the 
search was completed, the abstract of each identified publication was reviewed to determine 
relevance. From these studies, we selected literature that included analysis of drug levels or drug 
effect in patient tumor tissue. All of these studies were obtained and their reference lists were 




animal studies. We eliminated any duplicate subject cohorts reported in more than one publication. 
Additionally, a search in the ClinicalTrials.gov registry returned a list of studies that met our 
above-mentioned search criteria, and the available ongoing trial information. Additional trials were 
identified by the personal knowledge of each of the authors. 
 
Data extraction 
Using a pre-designed data extraction sheet, two reviewers (DK and HB-R) extracted the data from 
included studies. A third reviewer (MAV) reviewed the search results and extracted data. Summary 
data that were extracted from the selected studies included the following: the journal name, the 
first author’s name, country, searching database, search terms, language limitation, additional 
retrieval, study sample and design, patient numbers, drug that was used in the study, dose of the 
drug, systemic dose of drug used in other studies, the schedule of the drug administration prior to 
the surgery, drug blood level, the level of the drug in tumor tissue and physiologic effect of the 




Twenty-two publications14-35 were identified that examined drug pharmacodynamics and/or 
pharmacokinetics in patients with glioblastoma. They are presented in chronological order, 
according to date of publication, and summarized in Table 2.   
 
Eleven (50%) studies included patients with glioblastoma only, 9 (41%) with any WHO III or IV 




included patients with recurrent tumors only, 3 (14%) with newly diagnosed only, 1 (4%) with 
either and 1 (4%) study did not specify the timing of disease.  The studies were relatively small 
with most occurring in the Phase I setting.  The maximum patient number was 30 and the smallest 
study included 3 patients.  The average sample size was 12.   
 
Therapeutics that have been subjected to tissue-based pharmacokinetic or pharmacodynamics 
evaluations had a variety of mechanisms of action ranging from conventional cytotoxic agents to 
more recently developed targeted agents. Five (23%) studies investigated conventional cytotoxic 
chemotherapy agents, while 15 (68%) investigated agents that were targeted against specific cell 
surface receptors or signaling cascades.  Two (9%) studies investigated an agent that reduces 
MGMT activity (O6-BG).  Twelve (54%) studies included multiple doses of the study agent prior 
to surgical sampling, whereas 8 (36%) studies provided drug in a single dose only prior to surgery, 
and 1 (4%) study that involved 2 drugs involved multiple doses of one drug and a single dose of 
the second drug prior to surgery.  One (4%) study involved the use of microdialysis and the study 
drug was given continuously during this form of monitoring.   
 
Eleven (50%) studies were performed using a dose of drug that was found to be the maximum 
tolerated dose or the usual clinical dose in prior studies.  Three (14%) studies involved dose 
escalation and hence provided either subclinical or clinical doses prior to surgery.  Six (27%) 
studies provided subclinical doses, and 2 (9%) studies provided doses higher than the conventional 





Tissue samples were obtained from enhancing tumor in 21 (95%) studies, non-enhancing tumor in 
6 (27%) studies and from cyst fluid in 1 (4%) one study.  One (4%) study involved microdialysis 
and no tissue samples were obtained.  Drug levels were assessed in tumor and/or tumor infiltrated 
brain in 17 (77%) studies.  Biological assessments of drug activity in tumor tissue were performed 
in 15 (68%) studies. 
 
Ongoing clinical trials 
 
A list of 14 clinical trials that include the collection of tumor specimens after a short course of pre-
operative treatment and that are open at the time of manuscript writing (February, 2020) is 
presented in Table 3.   
 
Nine (64%) trials enroll patients with glioblastoma only, and 4 (29%) permit any high grade 
glioma; one (7%) trial is open for meningiomas.   Nearly all include patients in the recurrent setting 
only.  One (7%) trial includes patients with brain metastases from solid tumors, in addition to 
gliomas. There is a large variability in pre-surgical regimens of experimental drug administration, 
and 9 of the studies do not specify the exact dose of the drug that they intend to use, although for 
most of those it is because the tissue-based study is within the context of a phase 1 dose escalation 
design.  
 
All clinical trials are collecting blood samples to characterize the pharmacokinetics of the study 
drug and 4 (29%) explicitly mention that tumor samples will be obtained and analyzed for tumor 




enhancing and non-enhancing tumor compartments. The majority of these trials are designed to 
assess biological impact of the drug on the tumor. Seven (50%) studies specify that 
pharmacodynamic evidence of drug action will be evaluated in the study. Methods vary among 
different studies and are tailored to the mechanism of the drug action. Some of the employed 
techniques include immunohistochemistry assessment of phosphorylation levels of key proteins, 
activation of apoptosis pathways, Ki-67 staining to assess tumor proliferative activity, or 
assessment of lymphocyte infiltration in studies assessing immunotherapy drugs.  
 
Discussion 
In this review, we identified 21 published studies that assessed tissue-based pharmacokinetic and 
pharmacodynamics parameters of experimental chemotherapeutics used to treat patients with brain 
tumors.  While these studies were not identified as “phase 0” at the time of publication, they meet 
many, but not all, of the classical criteria for this designation. Notably, these studies were published 
over a 25-year time-period; hence, there has been fewer than one published “phase 0” study per 
year in neuro-oncology despite previous calls for more of these types of trials36,37.  Given the 
known challenges associated with systemic delivery of therapeutics to the brain, it should not come 
as a surprise that the paucity of investigations into the pharmacodynamics of brain tumor-targeted 
experimental therapeutics associates with the overall lack of success in therapeutic development 
in this field.  Indeed, the lack of phase 0 investigations may even be predictive of the general failure 
to make substantial progress in finding effective treatments for gliomas. 
 
An important point to consider with respect to brain tumor tissue collection is the amount and 




biopsies typically provide limited amounts of tissue that may not be sufficient for accurate drug 
level analysis, tissue preservation for immunohistochemistry, and biochemical studies. One 
example of a study that was limited in its ability to provide meaningful information on tissue 
distribution is that published by Wen et al.28 Their disappointing experience with this trial led them 
to adjust future protocols to ensure that sufficient tissue is obtained in a higher percentage of 
patients.  Indeed, we believe that this experience supports a requirement for neuro-oncology phase 
0 studies to be conducted in the setting of a planned tumor resection only. 
 
Pharmacokinetic and pharmacodynamic approaches have been used to assess drug delivery 
including assessment of tumor and CSF drug levels and assessment of drug effects.  Tumor tissue 
drug levels were measured in 16 studies. Three studies obtained samples from different areas of 
the brain tumor including from solid tumor  and tumor-adjacent brain tissue,16,17 or enhancing and 
non-enhancing tumor components,21 whereas others relied on samples from solid tumor tissue 
only. Given the unique therapeutic challenge in neurooncology posed by the presence of the blood-
brain-barrier, it is important to obtain samples from both enhancing and non-enhancing tumor 
components, as the concentration of the drug, and hence effectiveness of therapy, may be 
substantially different in those two areas.  These two areas are illustrated with use of relevant MRI 
images in Figure 1. For example, a phase 0/1 study of a Notch inhibitor in newly diagnosed WHO 
grade III or IV glioma showed that the levels in non-enhancing and enhancing tumor differed 
substantially.31 In two other studies that evaluated adjacent brain tissue, similar drug levels were 
observed within tumor and in normal brain.16,17  One study used microdialysis to evaluate drug 
distribution in enhancing and non-enhancing portions of the tumor, and noted very different 




of the tumor.21 These disparate results may reflect differences in the chemistry of the drugs 
evaluated in the various studies but support the need to evaluate both tumor core and tumor 
infiltrated brain to paint a complete picture of drug distribution.  Most notably, these studies do 
not account for the challenge of differentiating intravascular drug from that which is truly within 
the tumor interstitial space.13,38-40  Nonetheless, in the context of gliomas, which have both solid 
and brain infiltrating components, complete assessment of drug penetration/effects must include 
sampling of both enhancing and non-enhancing tumor tissue.  Simultaneously, for early stage trials 
of systemically delivered therapeutics in neuro-oncology patients it is always necessary to also 
evaluate peripheral PK at the same time as CNS PK measurements are obtained, even when the 
systemic PK for the same dose has been well established in other cancers.  It has been well 
documented that the peripheral PK of some therapeutics can be impacted by certain classes of 
drugs used extensively in the neuro-oncology patient population (e.g. liver enzyme-inducing anti-
epileptic drugs).41 
 
Because of the challenges associated with interpretation of drug level measurements alone in 
clinical tissues, a more compelling argument for proof of delivery comes in the form of 
pharmacodynamics assays. Few studies included an evaluation of drug effect on tumor tissue, and 
many of those that did, presented a more complete, yet complex picture.  For example, while 
gefinitib appeared to be capable of inhibiting phosphorylation of EGFR in enhancing glioma 
tissue, the critical parts of the downstream signal transduction pathway were unaffected.24 This 
result is instructive in that it suggested that the clinical failure of this signal transduction approach 
may have been due to a complex biology more so than drug delivery. Similar observations were 




phosphorylated signal transduction proteins that were similar to those observed in tumors that were 
naïve to the drug.26,28,34 Yet studies that included the use of tissue-based assays of drug effect were 
in the minority – most studies were not designed to provide, or were not capable of providing,28,31 
treated tissues for mechanistic analyses.    
 
Another limitation to some of the studies performed to date is lack of relevant baseline (control) 
data that would be essential for interpreting the experimental result.  For example, the studies that 
evaluated the utility of O6-BG were not designed to provide a baseline assessment, either directly 
or indirectly via assessment of MGMT promoter methylation assay, of MGMT activity.15,19 
Similarly, studies of signal transduction inhibitors ideally should include an assessment of target 
activity prior to treatment.  Reardon et al. used archival specimens from tumors that were treatment 
naïve, whereas subsequent medical treatments may have changed tumor phenotype at recurrence.26 
This reliance on what may be an outdated specimen for baseline assessments is one of the 
challenges inherent to the field of neuro-oncology.  Another way to approach this issue is to 
randomize patients with respect to pre-surgical treatment followed by surgery with tissue 
harvesting for assessment of relevant treatment targets.  In this manner, tumor not exposed to drug 
can be compared to tumor treated with the drug, with the caveat that these tumors are not derived 
from the same patient. 
 
Another challenge associated with Phase 0 trials, in general, which is likely to be even more 
challenging in neuro-oncology trials is that of appropriate statistical powering of 
pharmacodynamic analyses.  For conventional phase 0 studies, there is a well-recognized problem 




For neuro-oncology trials, this risk is even higher due to the limited sampling of target tissues that 
can be performed, usually at only one time point and without same-patient, pre-treatment control 
tissue samples.  In addition, the challenges of tissue heterogeneity of response are likely to be 
larger in brain tumors than in their systemic counterparts due to the presence of a blood-tumor-
barrier that can provide variable permeability to most agents.  Finally, it can be challenging to 
determine what magnitude of pharmacodynamic response needs to be observed in order to properly 
power the analysis.  As shown in several trials that evaluated pharmacodynamic responses, the 
correlation between pharmacodynamic and clinical responses in neuro-oncology trials has been 
poor.  Perhaps a better strategy is dichotomize results for go-no go decision-making – that is, lack 
of evidence of any target-specific biological effect should eliminate the agent from further 
evaluation (at least via the systemic route of administration).  While the presence of an effect, even 
if substantial, is not a guarantee of clinical activity, at least it is an indicator of the ability of the 
agent to impact on tumor tissue. 
 
Some phase 0/window of opportunity trials involve use of pre-surgical treatment only with the 
explicitly stated intent to determine the biological, but not clinical, impact of a novel therapy.  The 
use of any therapeutic in a cancer patient is often defined as a “regimen” and so a 
pharmacodynamic-only study design may result in the patient being excluded from subsequent 
trials due to the number of prior regimens.   In neuro-oncology, the use of a pharmacdynamic-only 
trial design is rare, but in line with these types of trials that are used in systemic cancer, a trial that 
intends to collect pharmacodynamic data only and that is unlikely to produce a drug-induced 





Overall, the experience to date suggests that several key components must be present in a phase 0 
clinical trial in neuro-oncology in order to identify systemically administered therapeutics that are 
capable of crossing the blood brain respectively tumor barrier, accumulate in tumor tissue, and 
exert pharmacodynamic effects on tumor biology. Table 4 summarizes the major components of 
phase 0 clinical trial design specifically pertaining to phase 0/window of opportunity clinical trial 
design in neuro-oncology. Specifically, when protocols include tumor tissue analysis of drug 
levels, these assessments should be performed in a variety of tumor sub-environments (enhancing 
and non-enhancing, central and peripheral, and tumor-adjacent areas).  Sampling from these 
separate areas is not expected to add time to the tumor resection procedure as they are already 
regions that are either removed or visually assessed by the neurosurgeon in the course of the 
operation.  The assessment of tumor drug levels alone without a parallel effort to assess the activity 
of the drug on tumor tissue, however, should be discouraged as drug levels are only one important 
variable potentially impacting on the overall efficacy of a study drug for CNS tumor patients.  
Other factors must be taking into account, including drug kinetics, binding to serum or tissue 
proteins, timing of sample collection with respect to last dose, and tissue sample contamination 
with intravascular drug, to name a few.  Ideally, all phase 0 trials in neuro-oncology should include 
measurements of the biological effects of the drug, including demonstration of the effect of the 
drug on cell viability and proliferation potential, but mostly focused on validation of drug-specific 
target effects. These assays should be supported by robust preclinical studies that confirm their 
validity and reliability in the in vivo setting, and they may be supplemented by techniques to 
perform noninvasive, imaging based evaluations of drug effect on tumor tissue44,45.  The study 
protocol should also include a discussion of what constitutes a positive or negative result with the 




requirements (volume, timing between collection and assay) for successful implementation of the 
assay in the clinical setting need to be specified.  Ultimately, challenges associated with systemic 
therapeutic delivery to brain tumors, particularly their infiltrative components that are protected 
by the blood brain barrier, rise to the level of making treated tissue-based assessments essential for 




The phase 0 clinical trial approach is an under-utilized strategy for the development of systemically 
administered therapeutics in neuro-oncology.  Few trials incorporate tissue-based assessment of 
drug penetration and pharmacodynamics in a field where there are unique and substantial 
biological barriers that prevent drug access to tumor and tumor-infiltrated brain.  In addition, there 
has been substantial heterogeneity in pharmacodynamics approaches and some of the strategies 
available for the development of therapeutics for systemic cancers are not appropriate for gliomas.  
Tissue-based assessments of biological effects of treatment should be strongly supported early in 
the course of the clinical development of novel therapeutics.   
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Figure 1:  MRI images that demonstrate the enhancing (left, T1 weighted MRI with contrast) and 




Characteristics of a classically defined phase 0 clinical trial 
First-in-human 
Small number of patients (<15) 
Limited time of drug exposure (< 7 days) 
Microdosing 
No therapeutic intent 




Table 2. Summary of studies (1993-2019) that examined tumor tissue post administration of the study drug 
 
Study # of 
Pati
ents 
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Temsirolimus  170-250 
mg IV  
















Methotrexate 12 g/m2, 
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Imatinib  400 mg 
orally bid 
for 7 days 
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Bortezomib  Phase II 1.7 
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Clinical Daily for 





























PLX3397 1000 mg 
PO daily 












































































on day 8, 




















AZD1775 100, 200, 
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Pathology Drug Dose Schedule 
prior to 
surgery 
Specimens Physiologic effect 
NCT01849146 Phase 1 
 









pRb expression, Ki-67, 
pCDC2, cleaved caspase 3 
NCT01986348 Phase 2 
 






























Tumor Total and phospho-EGFR, Ki-
67 
NCT02133183 Phase 1 
 










ICH for pS6, p4EBP, pmTOR, 
and AKTpSer473; PK in 
enhancing tumor 
NCT02337686 Phase 2 
 











polyfunctional effector T 
cells:Treg ratio 
NCT02525692 Phase 2 
 
76 Recruiting Recurrent 
glioblastoma 







Tumor Not specified 
NCT02630030 Phase 0 
 










Tumor PK in tumor tissue 
NCT02850744 Phase 2 
 











PK in CSF 
NCT02852655 Pilot 
 
35 Active, not 
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blood 
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pRB expression level 
NCT03122197 Phase 
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PK parameters in tumor tissues 
NCT03107780 Phase 
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Table 4. Key components proposed for phase 0/window of opportunity trials in neuro-oncology 
Patients undergoing a planned tumor resection 
Use clinical dose of drug 
Perform comprehensive tumor drug level measurement 
 Enhancing tumor component 
Non-enhancing tumor component 
Tumor-adjacent areas 
Consider microdialysis for compounds suitable for this method 
Always evaluate the biological effect of the drug 







Typical site for sampling 
(enhancing tumor)
Additional sites that should 
be considered for sampling 
(non-enhancing tumor)
